CB1

CB1 is the main cannabinoid receptor in the brain but is also found in other tissues. CB1 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently reduces cAMP upon activation. This in turn regulates many second messenger pathways. 

CBG

CBG is a non-psychoactive cannabinoid with therapeutic potential in cancer, Huntington's Disease, eating disorders, gastrointestinal inflammation, glaucoma and Psoriasis.

Epilepsy

cannabinoids have excellent therapeutic potential for the treatment of epilepsy. In the brain, the endocannabinoid system tends to keep neuronal activity wihtin acceptable boundaries.

TRPV3

TRPV3 is one of the non-GPCR-coupled cannabinoid receptors. TRPs are typically involved in pain sensation.

α2r

α2 receptors are classically known as adrenalin receptors. However, α2 receptors also bind CBG at very high affinity and are therefore also cannabinoid receptors. The interaction between CBG and α2 receptors may be relevant in the treatment of pain and depression, but more research is required.

TRPM8

TRPM8 is involved in sensory perception.

TRPA1

TRPA1 is best known as a sensor for environmental irritants, pain, cold and stretch.

CB2

CB2 is primarily expressed in the immune cells and tissues of the body. Like CB1, CB2 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently lowers cAMP upon activation. This, in turn, regulates many second messenger pathways.

Pain

pain is a very good target for therapeutic cannabinoids.

Psoriasis

Psoriasis is an auto-immune disease characterized by itchy skin lesions. Psoriasis arises when the immune system mistakenly identifies skin cells as foreign matter and causes over-production of new skin cells.